Brief: Brii Bio Announces Positive Data Demonstrating Its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 Subvariant
09/05/2022 12:53
May 9 (Reuters) - Brii Biosciences Ltd 2137.HK :
* BRII BIO ANNOUNCES POSITIVE DATA DEMONSTRATING ITS
LONG-ACTING
COVID-19 NEUTRALIZING ANTIBODY THERAPY, AMUBARVIMAB/ROMLUSEVIMAB
COMBINATION, RETAINS NEUTRALIZING ACTIVITY AGAINST OMICRON BA.2
SUBVARIANT
* BRII BIOSCIENCES - STUDIES CONDUCTED BY INDEPENDENT LABS
SHOW
AMUBARVIMAB/ROMLUSEVIMAB COMBINATION RETAINS NEUTRALIZING
ACTIVITY AGAINST OMICRON VARIANT
Source text for Eikon: ID:nPn1sQVnca
Further company coverage: 2137.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brii Biosciences
See all newsBrief: BRII Biosciences Discloses Launch Of BRISC, An SIRNA Therapeutics Discovery Platform
China's Brii Biosciences interim net loss narrows on lower R&D expenses
Brief: Brii Biosciences Announces Share Buy-Back Programme No More Than HK$60 Million
Brief: Brii Biosciences Says Arbitration Between Brii And Vir Remains In Early Stages With No Resolution
Brief: Brii Biosciences Submits Demand For Arbitration Against VIR